Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm

Patients with aplastic anemia or hypoplastic myelodysplastic syndrome (MDS) may respond to immunosuppressive therapy, including the anti-CD52 antibody alemtuzumab. We analyzed treatment responses to alemtuzumab in 5 patients with MDS or aplastic anemia (AA) evolving to MDS. Two patients with hypopla...

Descripción completa

Detalles Bibliográficos
Autores principales: Füreder, Wolfgang, Cerny-Reiterer, Sabine, Sperr, Wolfgang R., Müllauer, Leonhard, Jäger, Eva, Schwarzinger, Ilse, Geissler, Klaus, Valent, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486731/
https://www.ncbi.nlm.nih.gov/pubmed/27743175
http://dx.doi.org/10.1007/s00508-016-1091-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486731/
https://www.ncbi.nlm.nih.gov/pubmed/27743175
http://dx.doi.org/10.1007/s00508-016-1091-9

Ejemplares similares